Руководство по диагностике и лечению легочнойартериальной гипертензии

1. Simonneau G., Galie N., Rubin L. et al. Clinical classification of pulmonary arterial hypertension. J. Am. Coll. Cardiot. 2004; 43: S5-12.

2. D'Alonzo G.E., Barst R.J., Ayres SM et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann. Intern. Med. 1991; 115: 343-349.

3. Rubin L.J. Primary pulmonary hypertension, N. Eng. J. Med. 1997; 336: 111-117.

4. Galie N., Manes A., Uguccioni L. et al. Primary pulmonary hypertension: insights into pathogenesis from epidemiology. Chest 1998; 114 (3 Suppl): 184S-94S.

5. Pietra G.G., Edwards W.D., Kay J.M. et al. Histopathology of primary pulmonary hypertension. A qualitative and quantitative study of pulmonary blood vessels from 58 patients in the National Heart, Lung, and Blood Institute, Primary Pulmonary Hypertension Registry [see com ments]. Circulation 1989; 80: 1198-1206.

6. Pietra G.G., Capion F., Stewart S. et al. Pathologic assessment of vascutopathies in pulmonary hypertension. 2004. 525-532.

7. Humbert M., Morrell N., Archer S. et al. Cellular and molecular pathobiology of pulmonary arterial hypertension. J. Am. Coll. Cardiot. 2004: 43: 513-524.

8. Lane K.B., Machado R.D., Pauciulo M.W. et al. Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension. The International PPH Consortium, Not Genet 2000; 26: 81-84.

9. Deng Z., Morse J.H., Slager SL et al. Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-ll gene. Am. J. Hum. Genetr. 2000; 67: 737-744.

10. Budhiraja R., Tuder R.M., Hassoun P.M. Endothelial dysfunction in pulmonary hypertension. Circulation 2004; 109: 159-165.

11. Barst R., McGoon M., Torbicki A. et al. Diagnosis and differential assessment of pulmonary arterial hypertension. J. Am. Coll. Cardiol. 2004; 43: S40-47.

12. Hoeper M., Oudiz R., Peacock A. et al. Endpoints and clinical trial designs in pulmonary arterial hypertension: clinical and regulatory perspectives. J. Am. Coll. Cardiol. 2004; 43: 548-555.

13. Galie N., Manes A., Branzi A. Prostanoids for pulmonary arterial hypertension. Am. J. Respir. Med. 2003; 2: 123-137.

14. Galie N., Manes A., Branzi A. The endothelin system in pulmonary arterial hypertension. Cardiovasc. Res. 2004; 61: 227-237.

15. Sastry B.K.S., Narasimhan C., Reddy N.K. et al. Clinical efficacy of sildenafil in primary pulmonary hypertension*1: A randomized, placebo-controlled, double-blind, crossover study. J. Am. Coll. Cardiol. 2004; 43: 1149-1153.

16. Committee for Practice Guidelines (CPG) of the European Society of Cardiology. Recommendations for Task Force Creation and Report Production A document for Task Force members and expert panels responsible for the creation and production of Guidelines and Expert Consensus Documents Committee for Practice Guidelines (CPG) of the European Society of Cardiology; 2003. http:// www.escardio.org

17. Hatano S., Strasser T. World Health Organization 1975 primary pulmonary hypertension. Geneva: WHO; 1975.

18. Fishman A.P. Primary pulmonary arterial hypertension: a look back. J. Am. Coll. Cardiol. 2004; 43: S2-4.

19. Humbert M., Nunes H., Sitbon 0. el al. Risk factors for pulmonary arterial hypertension. Ctin. Chest Med. 2001: 22: 459-475.

20. Hoeper M.M., Niedermeyer J., Hoffmeyer F. et al. Pulmonary hypertension after splenectomy? Ann. Intern. Med. 1999; 130: 506-509.

21. Castro 0., Hoque M., Brown B.D. Pulmonary hypertension in sickle cell disease: cardiac catheterization results and survival. Blood 2003; 101: 1257-1261.

22. Atichartakarn V., Likittanasombat K., Chuncharunee S. et al. Pulmonary arterial hypertension in previously splenectomized patients with beta-thalassemic disorders. Int. J. Hematol. 2003; 78: 139-145.

23. Dingli D., Utz J.P., Krowka M.J. et al. Unexplained pulmonary hyperten sion in chronic myeloproliferative disorders. Chest 2001; 120: 801-808.

24. Humbert M., Labrune P., Simonneau G. et al. Pulmonary arterial hypertension and type I glycogen storage disease: the serotonin hypothesis. Eur. Respir. J. 2002; 20: 59-65.

25. Dawson A., Elias D.J., Rubenson D. et al. Pulmonary hypertension developing after alglucerase therapy in two patients with type 1 Gaucher disease complicated by the hepatopulmonary syndrome. Ann. Intern. Med. 1996: 125: 901-904.

26. Trembath R.C., Thomson J.R., Machado R.D. et al. Clinical and molecular genetic features of pulmonary hypertension in patients with hereditary hemorrhagic telangiectasia. N. Eng. J. Med. 2001; 345: 325-334.

27. Daliento L., Somerville J., Presbitero P. et al. Eisenmenger syndrome. Factors relating to deterioration and death. Eur. Heart. J. 1998; 19: 1845-1855.

28. Besterman E. Atrial septal defects with pulmonary hypertension. Br. Heart J. 1961; 23: 587-598.

29. Hoffman J.E., Rudolph A.M. The natural history of ventricular septal defects in infancy. Am. J. Cardiol. 1985; 16: 634-653.

30. Steele P., Fuster V., Cohen M. et al. Isolated atrial septal defect with pulmonary vascular obstructive disease: long-term follow-up and prediction of outcome after surgical correction. Circulation 1987; 76: 1037-1042.

31. Vogel M., Berger F., Kramer A. et al. Incidence of secondary pulmonary hypertension in adults with atrial septal or sinus venosus defects. Heart 1999; 82: 30-33.

32. Kidd L., Driscoll D., Gersony W. et al. Second natural history study of congenital heart defects. Results of treatment of patients with ventricular septat defects. Circulation 1993; 87: 138-151.

33. Neumayer U., Stone S., Somerville J. Small ventricular septal defects in adults. Eur. Heart J. 1988; 19: 1573-1582.

34. Wood P. Primary pulmonary hypertension, with special reference to the vasoconstrictive factor. Br. Heart J. 1958; 20: 557-565.

35. Yuan J.X., Aldinger A.M., Juhaszova M. et al. Dysfunctional voltage-gated K+ channels in pulmonary artery smooth muscle cells of patients with primary pulmonary hypertension. Circulation 1998; 98: 1400-1406.

36. Petkov V., Mosgoeller W., Ziesche R. et al. Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension. J. Clin. Invest. 2003; 111: 1339-1346.

37. Cowan K.N., Heilbut A., Humpl T. et al. Complete reversal of fatal pulmonary hypertension in rats by a serine elastase inhibitor. Nat. Med. 2000; 6: 698-702.

38. Du L., Sullivan C.C., Chu D. et al. Signaling molecules in nonfamilial pulmonary hypertension. N. Efig. J. Med. 2003; 348: 500-509.

39. Dorfmuller P., Perros F., Balabanian K. et al. Inflammation in pulmonary arterial hypertension. Eur. Respir. J. 2003: 22: 358-363.

40. Eddahibi S., Humbert M., Fadel E. et al. Serotonin transporter overexpression is responsible for pulmonary artery smooth muscle hyperplasia in primary pulmonary hypertension. J. Clin. Invest. 2001; 108: 1141-1450.

41. Friedman R., Mears J.G., Barst R.J. Continuous infusion of prostacyclin normalizes plasma markers of endothelial cell injury and platelet aggregation in primary pulmonary hypertension. Circulation 1997; 96: 2782-2784.

42. Eisenberg P.R., Lucore C., Kaufman L. et al. Fibrinopeptide: A levels indicative of pulmonary vascular thrombosis in patients with primary pulmonary hypertension. Circulation 1990; 82: 841-847.

43. Christman B.W., McPherson C.D., Newman J.H. et al. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension [see comments]. N. Eng. J. Med. 1992; 327: 70-75.

44. Thomson J.R., Trembath R.C. Primary pulmonary hypertension: the pressure rises for a gene. J. Clin. Pathol. 2000; 53: 899-903.

45. Tsukada T., Yokoyama K., Arai T. et al. Evidence of association of the ecNOS gene polymorphism with plasma NO metabolite levels in humans. Biochem. Biophys. Respir. Commun. 1998; 245: 190-193.

46. Pearson D.L., Dawling S., Walsh W.F. et al. Neonatal pulmonary hypertension - ureacycle intermediates, nitric oxide production, and carbamoyl-phosphate synthetase function. N. Eng. J. Med. 2001; 344: 1832-1838.

47. Chaouat A., Coulet F., Favre С. et al. Endoglin germline mutation in a patient with hereditary hemorrhagic telangiectasia and dexfenfluramine-associated pulmonary arterial hypertension. Thorax 2004; 59: 446-448.

48. Rich S., Dantzker D.R., Ayres S.M. et al. Primary pulmonary hypertension. A national prospective study. Ann. Intern. Med. 1987; 107: 216-223.

49. MacGregor A.J., Canavan R., Knight С. et al. Pulmonary hypertension in systemic sclerosis: risk factors for progression and consequences for survival. Rheumatol. (Oxford) 2001; 40: 453-459.

50. Ahearn G.S., Tapson V.F., Rebeiz A. et al. Electrocardiography to define clinical status in primary pulmonary hypertension and pulmonary arterial hypertension secondary to collagen vascular disease. Chest 2002; 122: 524-527.

51. Ommen S.R., Nishimura R.A., Hurrell D.G. et al. Assessment of right atrial pressure with 2-dimensional and Doppler echocardiography: a simultaneous catheterization and echocardiographic study. Mayo Clin. Proc. 2000; 75: 24-29.

52. Borgeson D.D., Seward J.B., Miller Jr F.A. et al. Frequency of Doppler measurable pulmonary artery pressures. J. Am. Soc. Echocardiogr. 1996; 9: 832-837.

53. Denton C.P., Cailes J.B., Phillips G.D. et al. Comparison of Doppler echocardiography and right heart catheterization to assess pulmonary hypertension in systemic sclerosis. Br. J. Rheumatol. 1997; 36: 239-243.

54. Vachiery J.L., Brimioulle S., Crasset V. et al. False-positive diagnosis of pulmonary hypertension by Doppler echocardiography. Eur. Respir. J. 1998; 12: 1476-1478.

55. McQuillan B.M., Picard M.H., Leavitt M. et al. Clinical correlates and reference intervals for pulmonary artery systolic pressure among echocardiographically normal subjects. Circulation 2001; 104: 2797-2802.

56. Mukerjee D., St.George D., Knight С. et al. Echocardiography and pulmonary function as" screening tests for pulmonary arterial hypertension in systemic sclerosis. Rheumatol. 2004; 43: 461-466.

57. Hinderliter A.L., Willis P.W., Barst R.J. et al. Effects of long-term infusion of prostacyclin (epoprostenol) on echocardiographic measures of right ventricular structure and function in primary pulmonary hypertension. Primary Pulmonary Hypertension Study Group [see comments]. Circulation 1997; 95: 1479-1486.

58. Galie N., Hinderliter A.L., Torbicki A. et al. Effects of the oral endothelin-receptor antagonist bosentan on echocardiographic and doppler measures in patients with pulmonary arterial hypertension. J. Am. Coll. Cardiol. 2O03; 41: 1380-1386.

59. Pauwels R.A., Buist A.S., Calverley P.M. et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am. J. Respir. Crit. Care Med. 2001; 163: 1256-1276.

60. Kazerooni E.A., Martinez F.J., Flint A. et al. Thinsection CT obtained at 10 mm increments versus limited three level thin section CT for idiopathic pulmonary fibrosis: correlation with pathologic scoring. AJR Am. J. Roentgenol. 1997; 169: 977-983.

61. Fedullo P.F., Auger W.R., Kerr K.M. et al. Chronic thromboembolic pulmonary hypertension. N. Eng. J. Med. 2001; 345: 1465-1472.

62. Resten A., Maitre S., Capron F. et al. Pulmonary hypertension: CT findings in pulmonary venoocclusive disease. J. Radiol. 2003; 84: 1739-1745.

63. Ley S., Kreitner K.F., Fink С. et al. Assessment of pulmonary hypertension by CT and MR imaging. Eur. Radiol. 2004; 14: 359-368.

64. Dartevelle P., Fadel E., Mussot S. et al. Chronic thromboembolic pulmonary hypertension. Eur. Respir. J. 2004; 23: 637-648.

65. Rich S., Kieras K., Groves В. et al. Antinuclear antibodies in primary pulmonary hypertension. J. Am. Coll. Cardiol. 1986; 8: 1307-1311.

66. Albrecht T., Blomley M.J., Cosgrove D.O. et al. Noninvasive diagnosis of hepatic cirrhosis by transit-time analysis of an ultrasound contrast agent. Lancet 1999; 353: 1579-1583.

67. Naeije R. Hepatoputmonary syndrome and portopulmonary hypertension. Swiss Medical Weekly 2003; 133: 163-169.

68. Miyamoto S., Nagaya N., Satoh T. et al. Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension. Comparison with cardiopulmonary exercise testing. Am. J. Respir. Crit. Care Med. 2000; 161: 487-492.

69. Wensel R., Opitz C.F., Anker S.D. et al. Assessment of survival in patients with primary pulmonary hypertension: importance of cardiopulmonary exercise testing. Circulation 2002; 106: 319-324.

70. Galie N., Manes A., Branzi A. The new clinical trials on pharmacological treatment in pulmonary arterial hypertension. Eur. Respir. J. 2002; 20: 1037-1049.

71. Peacock A., Naeije R., Galie N. et al. End-points for clinical trials in pulmonary arterial hypertension. Eur. Respir. J. 2004; 23: 947-953.

72. Guyatt G.H., Sullivan M.J., Thompson P.J. et al. The 6-minute walk: a new measure of exercise capacity in patients with chronic failure. Can. Med. Assoc. J. 1985; 132: 919-923.

73. Paciocco G., Martinez F., Bossone E. et al. Oxygen desaturation on the six-minute walk test and mortality in untreated primary pulmonary hypertension. Eur. Respir. J. 2001; 17: 647-652.

74. Barst R.J., McGoon M., Me Laughlin VV. et al. Beraprost therapy for pulmonary arterial hypertension. J. Am. Coll. Cardiol. 2003; 41: 2115-2125.

75. Barst R.J., Langleben D., Frost A. et al. Sitaxsentan therapy for pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med. 2004; 169: 441-447.

76. Sandoval J., Gaspar J., Pulido T. et al. Graded balloon dilation atrial septostomy in severe primary pulmonary hypertension. A therapeutic alternative for patients nonresponsive to vasodilator treatment. J. Am. Coll. Cardiol. 1998; 32: 297-304.

77. McLaughlin W., Shillington A., Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation 2002; 106: 1477-1482.

78. McLaughlin V., Sitbon O., Rubin L. et al. The effect of first-line Bosentan on survival of patients with primary pulmonary hypertension. Am. J. Respir. Crit. Care Med. 2003;1 67: A442.

79. Rich S., Kaufmann E., Levy P.S. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension [see comments]. N. Eng. J. Med. 1992; 327: 76-81.

80. Sitbon O., Humbert M., Jagot J.L. et al. Inhaled nitric oxide as a screening agent for safely identifying responders to oral calcium-channel blockers in primary pulmonary hypertension. Eur. Respir. J. 1998; 12: 265-270.

81. Sitbon O., Humbert M., Loos V. et al. Who benefits from long-term calcium-channel blocker therapy in primary pulmonary hypertension? Am. J. Respir. Crit. Care Med. 2003; 167.

82. Weir E.K., Rubin L.J., Ayres S.M. et al. The acute administration of vasodilators in primary pulmonary hypertension. Experience from the National Institutes of Health Registry on Primary Pulmonary Hypertension. Am. Rev. Respir. Dis. 1989; 140: 1623-1630.

83. Galie N., Ussia G., Passarelli P. et al. Role of pharmacologic tests in the treatment of primary pulmonary hypertension. Am. J. Cardiol. 1995; 75: 55A-62A.

84. McLaughlin V.V., Genthner D.E., Panella M.M. et al. Reduction in pulmonary vascular resistance with long- term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension [see comments]. N. Eng. J. Med. 1998; 338: 273-277.

85. Galie N., Seeger W., Naeije R. et al. Comparative analysis of clinical trials and evidencebased treatment algorithm in pulmonary arterial hypertension. J. Am. Coll. Cardiol. 2004; 43: S81-88.

86. Nootens M., Kaufman E., Rich S. Short-term effectiveness of nifedipine in secondary pulmonary hypertension. 1993. 1476.

87. Sitbon O., Humbert M., Nunes H. et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J. Am. Coll. Cardiol. 2O02; 4O: 780-788.

88. Eysmann S.B., Palevsky H.I., Reichek N. et al. Two-dimensional and Dopplerechocardiographic and cardiac catheterization correlates of survival in primary pulmonary hypertension. Circulation 1989; 80: 353-360.

89. Raymond R.J., Hinderiiter A.L., Willis P.W. et at. Echocardiographic predictors of adverse outcomes in primary pulmonary hypertension. J. Am. Coll. Cardiol. 2002; 39: 1214-1219.

90. Tei C., Dujardin K.S., Hodge D.O. et al. Doppler echocardiographic index for assessment of global right ventricular function [see comments]. J. Am. Soc. Echocardiogr. 1996; 9:838-847.

91. Yeo T.C., Dujardin K.S., Tei C. et al. Value of a Doppler-derived index combining systolic and diastolic time intervals in predicting outcome in primary pulmonary hypertension. Am. J. Cardiol. 1998; 81: 1157-1161.

92. Raffy О., Azarian R. Brenot F. et al. Clinical significance of the pulmonary vasodilator response during short-term infusion of prostacyclin in primary pulmonary hypertension. Circulation 1996; 93: 484-488.

93. Voelkel M.A., Wynne K.M., Badesch D.B. et al. Hyperuricemia in severe pulmonary hypertension. Chest 2000; 117: 19-24.

94. Nagaya N., Nishikimi T., Uematsu M. et al. Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. Circulation 2000; 102: 865-870.

95. Nootens M., Kaufmann E., Rector T. et al. Neurohormonal activation in patients with right ventricular failure from pulmonary hypertension: relation to hemodynamic variables and endothelin levels. J. Am. Coll. Cardiol. 1995; 26: 1581-1585.

96. Rubens C., Ewert R., Halank M. et al. Bigendothelin-1 and endothelin-1 plasma levels are correlated with the severity of primary pulmonary hypertension. Chest 2001; 120:1562-1569.

97. Torbicki A., Kurzyna M., Kuca P. et al. Detectable serum cardiac troponin T as a marker of poor prognosis among patients with chronic precapillary pulmonary hypertension. Circulation 2003; 108: 844-848.

98. Galie N. Do we need controlled clinical trials in pulmonary arterial hypertension? Eur. Respir. J. 2001; 17: 1-3.

99. Badesch B.D., Abman S.H., Ahearn G.S. et al. Medical therapy for pulmonary arterial hypertension. ACCP Evidence-Based Guidelines for Clinical Practice. Chest 2004; 126: 355-625.

100. Manes A., Galie N., Branzi A.Women and pulmonary arterial hypertension. Eur. Respir. J. (Monograph.) 2003; 8: 219-227.

101. Nelson D.M., Main E., Crafford W. et al. Peripartum heart failure due to primary pulmonary hypertension. Obstet. Gynecol. 1983; 62: 58s-63s.

102. Weiss B.M., Zemp L., Seifert B. et al. Outcome of pulmonary vascular disease in pregnancy: a systematic overview from 1978 through 1996. J. Am. Coll. Cardiol. 1998; 31: 1650-1657.

103. Nootens M., Rich S. Successful management of labor and delivery in primary pulmonary hypertension. Am. J. Cardiol. 1993; 71: 1124-1125.

104. Expert consensus document on management of cardiovascular diseases during pregnancy. Eur. Heart. J. 2003; 24: 761-781.

105. Abenhaim L. Moride Y., Brenot F. et al. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group [see comments]. N. Eng. J. Med. 1996; 335: 609-616.

106. Deanfield J., Thaulow E., Warnes C. et al. Management of grown up congenital heart disease. Eur. Heart J. 2003; 24: 1035-1084.

107. Sanguinetti M., Galie N., Magelli C. et al. Precapillary pulmonary hypertension: effect of Captopril. G. Ital. Cardiol 1982; 12: 436-441.

108. Girgis A., Sanson-Fisher R.W. Breaking bad news: consensus guidelines for medical practitioners. J. Clin. Oncol. 1995; 13: 2449-1256.

109. Stewart M., Davidson K., Meade D. et al. Group support for couples coping with a cardiac condition. J. Adv. Nurs. 2001; 33: 190-199.

110. Moser K.M., Fedullo P.F., Finkbeiner W.E. et al. Do patients with primary pulmonary hypertension develop extensive central thrombi? Circulation 1995; 91: 741-745.

111. Fuster V., Steele P.M., Edwards W.D. et al. Primary pulmonary hypertension: natural history and the importance of thrombosis. Circulation 1984; 70: 580-587.

112. Frank H., Mlczoch J., Huber K. et al. The effect of anticoagulant therapy in primary and anorectic drug-induced pulmonary hypertension. Chest 1997; 112: 714-721.

113. Badesch D.B., Tapson V.F., McGoon M.D. et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial [see comments]. Ann. Intern. Med. 2000; 132: 425-434.

114. Sandoval J., Aguirre J.S., Pulido T. et al. Nocturnal oxygen therapy in patients with the eisenmenger syndrome. Am. J. Respir. Crit. Care Med. 2001; 164: 1682-1687.

115. Rich S., Seidlitz M., Dodin E. et al. The short-term effects of digoxin in patients with right ventricular dysfunction from pulmonary hypertension. Chest 1998; 114: 787-792.

116. Naeije R., Vachiery F. Medical treatment of pulmonary hypertension. Clin. Chest Med. 2004; 22: 517-527.

117. Rich S., Brundage B.H. High-dose calcium channel-blocking therapy for primary pulmonary hypertension: evidence for long-term reduction in pulmonary arterial pressure and regression of right ventricular hypertrophy. Circulation 1987; 76: 135-141.

118. Barst R.J., Maislin G., Fishman A.P. Vasodilator therapy for primary pulmonary hypertension in children. Circulation 1999; 99: 1197-1208.

119. Rich S., Kaufmann E. High dose titration of calcium channel blocking agents for primary pulmonary hypertension: guidelines for short-term drug testing. J. Am. Coll. Cardiol. 1991; 18: 1323-1327.

120. Jones D.A., Benjamin C.W., Linseman D.A. Activation of thromboxane and prostacyclin receptors elicits opposing effects on vascular smooth muscle cell growth and mitogen-activated protein kinase signaling cascades. Mol. Pharmacol. 1995; 48: 890-896.

121. Barst R.J., Rubin U., Long W.A. et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group [see comments]. N. Eng. J. Med. 1996; 334: 296-302.

122. Rubin L.J., Mendoza J., Hood M. et al. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenot). Results of a randomized trial. Ann. Intern. Med. 1990; 112: 485-491.

123. Robbins I.M., Gaine S.P., Schilz R. et al. Epoprostenol for treatment of pulmonary hypertension in patients with systemic lupus erythematosus [see comments]. Chest 2000; 117: 14-18.

124. Mclaughlin W., Genthner D.E., Panella M.M. et al. Compassionate use of continuous prostacyclin in the management of secondary pulmonary hypertension: a case series [see comments]. Ann. Intern. Med. 1999; 130: 740-743.

125. Rosenzweig E.B., Kerstein D., Barst R.J. Long-term prostacyclin for pulmonary hypertension with associated congenital heart defects. Circulation 1999; 99: 1858-1865.

126. Kuo P.C., Johnson L.B., Plotkin J.S. et al. Continuous intravenous infusion of epoprostenol for the treatment of portopulmonary hypertension. Transplantation 1997; 63: 604-606.

127. Bakst A.E., Gaine S.P., Rubin L.J. Continuous intravenous epoprostenol therapy for pulmonary hypertension in Gaucher's disease. Chest 1999; 116: 1127-1129.

128. Aguilar R.V., Farber H.W. Epoprostenol (prostacyclin) therapy in HIV-associated pulmonary hypertension. Am. J. Respir. Crit. Care Med. 2000; 162:1846-1850.

129. Higenbottam T., Butt A.Y., McMahon A. et al. Long-term intravenous prostaglandin (epoprostenol or iloprost) for treatment of severe pulmonary hypertension. Heart 1998; 80: 151-155.

130. Simonneau G., Barst R.J., Galie N. et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension. A double-blind, randomized, placebo-controlled trial. Am. J. Respir. Crit. Care Med. 2002; 165: 800-804.

131. Mclaughlin V.V., Gaine S.P., Barst R.J. et al. Efficacy and safety of treprostinil: an epoprostenol analog for primary pulmonary hypertension. J.. Cardiovasc. Pharmacol. 2003; 41: 293-299.

132. Vachiery J.L., Hill N., Zwicke D. et al. Transitioning from i.v. epoprostenol to subcutaneous treprostinit in pulmonary arterial hypertension. Chest 2002; 121: 1561-1565.

133. Galie N., Humbert M., Vachiery J.L. et al. Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomised, double-blind placebo-controlled trial. J. Am. Coll. Cardiol. 2002; 39: 1496-1502.

134. Hoeper M.M., Olschewski H., Ghofrani H.A. et al. A comparison of the acute hemodynamic effects of inhaled nitric oxide and aerosolized iloprost in primary pulmonary hypertension. German PPH study group. J. Am. Coll. Cardiol. 2000; 35: 176-182.

135. Olschewski H., Simonneau G., Galie N. et al. Inhaled Iloprost in severe pulmonary hypertension. N. Eng. J. Med. 2002; 347: 322-329.

136. Hoeper M.M., Schwarze M., Ehlerding S. et al. Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyctin analogue. N. Eng. J. Med. 2000; 342: 1866-1870.

137. Olschewski H., Ghofrani H.A., Walmrath D. et al. Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to lung fibrosis. Am. J. Respir. Crit. Care Med. 1999; 160: 600-607.

138. Higenbottam T.W., Butt A.Y., Dinh7Xaun A.T. et al. Treatment of pulmonary hypertension with the continuous infusion of a prostacyclin analogue, iloprost. Heart 1998; 79: 175-179.

139. Ewert R., Opitz C., Wensel R. et al. Iloprost as inhalational and intravenous long-term treatment of patients with primary pulmonary hypertension. Register of the Berlin Study Group for Pulmonary Hypertension. Z. Kardiol. 2000; 89: 987-999.

140. Stewart D.J., Levy R.D., Cernacek P. et al. Increased plasma endothelin-1 in pulmonary hypertension: marker or mediator of disease? Ann. Intern. Med. 1941: 114: 464-469.

141. Giaid A., Yanagisawa M., Langleben D. et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N. Eng. J. Мed. 1993; 328: 1732-1739.

142. Clozel M., Breu V., Gray G.A. et al. In vivo pharmacology of Ro 46-2005, the first synthetic nonpeptide endothelin receptor antagonist: implications for endothelin physiology. J. Cardlovasc. Pharmacol. 1993; 22: S377-S379.

143. Channick R., Badesch D.B., Tapson V.F. et al. Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary hypertension: a placebo-controlled study. J. Heart Lung. Transplant. 20O1; 2O: 262-263.

144. Rubin L.J., Badesch D.B., Barst R.J. et al. Bosentan therapy for pulmonary arterial hypertension. N. Eng. J. Med. 2002; 346: 896-903.

145. Fattinger K., Funk C., Pantze M. et al. The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: A potential mechanism for hepatic adverse reactions. Gin. Pharmacol. Therapeutics 2001; 69: 223-231.

146. Sitbon 0., Badesch D.B., Channick R.N. et al. Effects of the dual endothetin receptor antagonist bosentan in patients with pulmonary arterial hypertension: a 1-year follow-up study. Chest 2003;124: 247-254.

147. Kim N.S., Channick R., Rubin L.J. Successful withdrawal of chronic epoprostenol therapy for pulmonary arterial hypertension. Chest 2003; 124: 1612-1615.

148. Barst R.J., Ivy D., Dingemanse J. et al. Pharmacokinetics, safety, and efficacy of bosentan in pediatric patients with pulmonary arterial hypertension. Clin. Pharmacol. Ther. 2003; 73: 372-382.

149. Barst R.J., Rich S., Widlitz A. et al. Clinical efficacy of sitaxsentan, an endothelin-A receptor antagonist, in patients with pulmonary arterial hypertension: open-label pilot study. Chest 2002; 121: 1860-1868.

150. Rubin L.J., Galie N., Badesch B.D. et al. Ambrisentan improves exercise capacity and clinical measures in pulmonary arterial hypertension (PAH). Am. J. Crit. Care Med. 2004; 169: A210. 06_2006_end.qxd 09.01.2007 14:32 Page 49 Руководство по диагностике и лечению легочной артериальной гипертензии 50 Пульмонология 6'2006

151. Corbin J.D., Francis S.H. Cyclic GMP phosphodiesterase-5: target of sildenafil. J. Biol. Chem. 1999; 274: 13729-13732.

152. Manes A., Tantini B., Galie N. et al. Effects of sildenafil on growth and viability of cultured human pulmonary artery smooth muscle cells. J. Am. Coll. Cardiol. 2OO3; 41: 223A.

153. Poison J.B., Strada S.J. Cyclic nucleotide phosphodiesterases and vascular smooth muscle. Ann. Rev. Pharmacol. Toxico.l 1996;.36: 403-427.

154. Cohen A.H., Hanson K., Morris К. et al. Inhibition of cyclic 3/-5/-guanosine monophosphate-specific phosphodiesterase selectively vasodilates the pulmonary circulation in chronically hypoxic rats. J. Clin. Invest. 1996; 97: 172-179.

155. Hanson K.A., Burns F., Rybalkin S.D. et al. Developmental changes in lung cGMP phosphodiesterase-5 activity, protein, and message. Am. J. Respir. Crit. Care Med. 1998; 158: 279-288.

156. Hanson K.A., Ziegler J.W., Rybalkin S.D. et al. Chronic pulmonary hypertension increases fetal lung cGMP phosphodiesterase activity. Am. J. Physiol. 1998; 275: L931-L941.

157. Prasad S., Wilkinson J., Gatzoulis M.A. Sildenafil in primary pulmonary hypertension. N. Eng. J. Med. 2000; 343: 1342.

158. Bhatia S., Frantz R.P., Severson C.J. et al. Immediate and long-term hemodynamic and clinical effects of sildenafil in patients with pulmonary arterial hypertension receiving vasodilator therapy. Mayo Clin. Proc. 2003; 78: 1207-1213.

159. Michelakis E.D., Tymchak W., Noga M. et al. Long-term treatment with oral sildenafil is safe and improves functional capacity and hemodynamics in patients with pulmonary arterial hypertension. Circulation 2003; 108: 2066-2069.

160. Ghofrani H.A., Schermuly R.T., Rose F. et al. Sildenafil for long-term treatment of nonoperable chronic thromboembolic pulmonary hypertension. Am. J. Respir. Crit. Care Med. 2003; 167:1139-1141.

161. Ghofrani H.A., Wiedemann R., Rose F. et al. Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial. Lancet 2002; 360: 895-900.

162. Ghofrani A., for the Sildenafil 1140 Study Group. Efficacy and safety of sildenafil citrate in pulmonary arterial hypertension: results of a multinational, randomized, double-blind, placebo-controlled trial; Am. Coll. Chest Physicians; 2004.

163. Humbert M., Barst R., Robbins I. et al. Combination of Epoprosterol and Bosentan in pulmonary arterial hypertension: BREATHE-2. Eur. Respir. J. 2004; 24: 353-359.

164. Hoeper M., Taha N., Bekjarova A. et al. Bosentan treatment in patients with primary pulmonary hypertension receiving nonparenteral prostanoids. Eur. Respir. J. 2003; 330-334.

165. Ghofrani H.A., Rose F., Schermuly R.T. et al. Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension. J. Am. Coll. Cardiol. 2003; 42: 158-164.

166. Austen W.G., Morrow A.G., Berry W.B. Experimental studies of the surgical treatment of primary pulmonary hypertension. J. Thorac. Cardiovasc. Sur. 1964; 48: 448-455.

167. Rozkovec A., Montanes P., Oakley C.M. Factors that influence the outcome of primary pulmonary hypertension. Br. Heart J. 1986; 55: 449-458.

168. Sandoval J., Rothman A., Pulido T. Atrial septostomy for pulmonary hypertension. Clin. Chest. Med. 2001; 22: 547-560.

169. Klepetko W., Mayer E., Sandoval J. et al. Interventional and surgical modalities of treatment for pulmonary arterial hypertension. J. Am. Coll. Cardiol. 2004; 43: S73-80.

170. Hertz M.l., Taylor D.O., Trulock E.P. et al. The registry of the International Society for Heart and Lung Transplantation: Nineteenth Official Report 2002. J. Heart Lung. Transplant. 2002; 21: 950-970.

171. Long W. Persistent pulmonary hypertension of the newborn syndrome. In: Long WA, editor. Fetal and neonatal cardiology. Philadelphia: WB Saunders; 1989. 627-655.

172. Weigel T.J., Hageman J.R. National survey of diagnosis and management of persistent pulmonary hypertension of the newborn. J. Perinatol. 1990; 10: 369-375.

173. Clark R.H., Kueser T.J., Walker M.W. et al. Low-dose nitric oxide therapy for persistent pulmonary hypertension of the newborn. Clinical Inhaled Nitric Oxide Research Group. N. Eng. J. Med. 20O0; 342: 469-474.

174. Walsh M.C., Stork E.K. Persistent pulmonary hypertension of the newborn. Rational therapy based on pathophysiology. Clin Perinatol 2001; 28: 609-627.. vii.

175. Sandoval J., Bauerle O., Gomez A. et al. Primary pulmonary hypertension in children: clinical characterization and survival. J. Am. Coll. Cardiol. 1995; 25: 466-474.

176. Gaine S.P., Rubin L.J. Primary pulmonary hypertension. Lancet 1998; 352: 719-725. [published erratum appears in Lancet 1999 Jan 2;353(9146):74].

177. Barst R., Ivy D., Widlitz A.C. et al. Pharmacokinetics, safety, and efficacy of bosentan in pediatric patients with pulmonary arterial hypertension. Clin. Pharmacol. Ther. 2003; 73: 372-382.

178. Abrams D., Schulze7Neick I., Magee A.G. Sildenafil as a selective pulmonary vasodilator in childhood primary pulmonary hypertension. Heart 2000; 84: E4.

179. Vongpatanasin W., Brickner M.E., Hillis L.D. et al. The Eisenmenger syndrome in adults. Ann. Intern. Med. 1998; 128: 745-755.

180. Hopkins W.E., Ochoa L.L., Richardson G.W. et al. Comparison of the hemodynamics and survival of adults with severe primary pulmonary hypertension or Eisenmenger syndrome. J. Heart Lung. Transplant. 1996; 15: 100-105.

181. Berman E.B., Barst R.J. Eisenmenger's syndrome: current management. Pros. Cardiovasc. Dis. 2002; 45: 129-138.

182. Sandoval J., Aguirre J.S., Pulido T. et al. Nocturnal oxygen therapy in patients with the Eisenmenger syndrome. Am. J. Respir. Crit. Care Med. 2001; 164: 1682-1687.

183. Brickner M.E., Hillis L.D., Lange R.A. Congenital heart-sease'in admits. Second of two parts. N EngJ Med 2000:342:334-42. [published erratum appears in N. Engl. J. Med. 2000 Mar 30;342(13):988].

184. Hadengue A., Benhayoun M.K., Lebrec D. et al. Pulmonary hypertension complicating portal hypertension: prevalence and relation to splanchnic hemodynamics. Castroenterotogy 1991; 100: 520-528.

185. Herve P., Lebrec D., Brenot F. et al. Pulmonary vascular disorders in portal hypertension. Eur. Respir. J. 1998; 11: 1153-1166.

186. Hoeper M.M., Krowka M.J., Strassburg C.P. Portopulmonary hypertension and hepatopulmonary syndrome. Lancet 2004; 363: 1461-1468.

187. McDonnell P.J., Toye P.A., Hutchins G.M. Primary pulmonary hypertension and cirrhosis: are they related. Am. Rev. Respir. Dis. 1983; 127: 437-441.

188. The International Primary Pulmonary Hypertension Study (IPPHS). Chest 1994; 105: 37S-41S.

189. Lebrec О., Capron JP., Dhumeaux D. et al. Pulmonary hypertension complicating portal hypertension. Am. Rev. Respir. Dis. 1979:120:849-56.

190. Ruttner J.R., Bartschi J.P., Niedermann R. et al. Plexogenic pulmonary arteriopathy and liver cirrhosis. Thorax 1980; 35: 133-136.

191. Kuo P.C., Plotkin J.S., Johnson L.B. et al. Distinctive clinical features of portopulmonary hypertension [see comments]. Chest 1997; 112: 980-986.

192. Robalino B.D., Moodie D.S. Association between primary pulmonary hypertension and portal hypertension: analysis of its pathophysiology and clinical, laboratory and hemodynamic manifestations. J. Am. ColI. Cardiol. 1991; 17: 492-498.

193. Plotkin J.S., Kuo P.C., Rubin L.J. et al. Successful use of chronic epoprostenol as a bridge to liver transplantation in severe portopulmonary hypertension. Transplantation 1998; 65: 457-459.

194. Krowka M.J., Frantz R.P., McGoon M.D. et al. Improvement in pulmonary hemodynamics during intravenous epoprostenol (prostacyclin): A study of 15 patients with moderate to severe portopulmonary hypertension. Hepatology 1999; 30: 641-648.

195. Findlay J.Y., Plevak D.J., Krowka M.J. et al. Progressive splenomegaly after epoprostenol therapy in portopulmonary hypertension. Liver Transpl. Surg. 1999; 5: 362-365.

196. Krowka M.J., Plevak D.J., Findlay J.Y. et al. Pulmonary hemodynamics and perioperative cardiopulmonary-related mortality in patients with portopulmonary hypertension undergoing liver transplantation. Liver Transpl. 2000; 6: 443-450.

197. Tan H.P., Markowitz J.S., Montgomery R.A. et al. Liver transplantation in patients with severe portopulmonary hypertension treated with preoperative chronic intravenous epoprostenol. Liver Transpl. 2001; 7: 745-749.

198. Pirenne J., Verleden G., Nevens F. et al. Combined liver and (heart) lung transplantation in liver transplant candidates with refractory portopulmonary hypertension. Transplantation 2002; 73: 140-142.

199. Schott R., Chaouat A., Launoy A. et al. Improvement of pulmonary hypertension after liver transplantation. Chest 1999; 115: 1748-1749.

200. Mitchell D.M., Miller R.F. AIDS and the lung: update 1995. 2. New developments in the pulmonary diseases affecting HIV infected individuals. Thorax 1995; 50: 294-302.

201. Mehta N.J., Khan I.A., Mehta R.N. et al. HIV-related pulmonary hypertension: analytic review of 131 cases. Chest 2000; 118: 1133-1141.

202. Mehta N.J., Khan I.A., Mehta R.N. et al. Acute coronary syndrome in patients with human immunodeficiency virus disease. Angiology 2002; 53: 545-549.

203. Opravil M., Pechere M., Speich R. et al. HIV-associated primary pulmonary hypertension. A case control study. Swiss HIV Cohort Study. Am. J. Respir. Crit. Care Med. 1997; 155: 990-995.

204. Humbert M., Monti G., Fartoukh M. et al. Platelet-derived growth factor expression in primary pulmonary hypertension: comparison of HIV seropositive and HIV seronegative patients. Eur. Respir. J. 1998; 11: 554-559.

205. Ehrenreich H., Rieckmann P., Sinowatz F. et al. Potent stimulation of monocytic endothelin-1 production by HIV-1 glycoprotein 120. J. Immunol. 1993; 150: 4601-4609.

206. Mette S.A., Palevsky H.I., Pietra G.G. et al. Primary pulmonary hypertension in association with human immunodeficiency virus infection. A possible viral etiology for some forms of hypertensive pulmonary arteriopathy. Am. Rev. Respir. Dis. 1992; 145: 1196-1200.

207. Tuder R.M., Groves B., Badesch D.B. et al. Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension. Am. J. Pathol. 1994; 144: 275-285.

208. Voelkel N.F., Cool C., Lee S.O. et al. Primary pulmonary hypertension between inflammation and cancer. Chest 1998; 114: 2255-2305.

209. Nunes H., Humbert M., Sitbon О. et al. Prognostic factors for survival in human immunodeficiency virus-associated pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med. 2003; 167: 1433-1439.

210. Petitpretz P., Brenot F., Azarian R. et al. Pulmonary hypertension in patients with human immunodeficiency virus infection. Comparison with primary pulmonary hypertension. Circulation 1994; 89: 2722-2727.

211. Speich R., Jenni R., Opravil M. et al. Regression of HIV-associated pulmonary arterial hypertension and long-term survival during antiretroviral therapy. Swiss Med. Wkly 2001; 131: 663-665.

212. Sitbon О., Gressin V., Speich R. et al. Bosentan in pulmonary arterial hypertension associated with HIV infection. Eur. Respir. J. 2003; 22: 563s.

213. Hoeper M., Galie N., Simonneau G. et al. New treatments for pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med. 2002; 165: 1209-1216.

214. Mukerjee D., St. George D., Coleiro B. et al. Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach. Ann. Rheum. Dis. 2003; 62: 1088-1093.

215. Pan T.L., Thumboo J., Boey M.L. Primary and secondary pulmonary hypertension in systemic lupus erythematosus. Lupus 2000; 9: 338-342.

216. Sanchez О., Humbert M., Sitbon О. et al. Treatment of pulmonary hypertension secondary to connective tissue diseases. Thorax 1999; 54: 273-277.

217. Fagan K.A., Badesch D.B. Pulmonary hypertension associated with connective tissue disease. Prog. Cardiovasc. Dis. 2002; 45: 225-234.

218. Yoshida S., Katayama M. Pulmonary hypertension in patients with connective tissue diseases. Nippon Rinsho 2001; 59: 1164-1167.

219. Humbert M., Sanchez О., Fartoukh M. et al. Short-term and long-term epoprostenol (prostacyclin) therapy In pulmonary hypertension secondary to connective tissue diseases: results of a pilot study. Eur. Respir. J. 1999; 13: 1351-1356.

220. Kuhn K.P., Byrne D.W., Arbogast P.G. et al. Outcome in 91 consecutive patients with pulmonary arterial hypertension receiving epoprostenol. Am. J. Respir. Crit. Care Med. 2003: 167: 580-586.

221. Oudiz R., Schilz R., Barst R. et al. Treprostinit, a prostacyclin analogue, in pulmonary arterial hypertension associated with connective tissue disease. Chest 2004; 126: 420-427.

222. Holcomb Jr B.W., Loyd J.E., Ely E.W. et at. Pulmonary venoocclusive disease: a case series and new observations. Chest 2000; 118: 1671-1679.

223. Langleben D., Heneghan J.M., Batten A.P. et al. Familial pulmonary capillary hemangiomatosis resulting in primary pulmonary hypertension. Ann. Intern. Med. 1988; 109: 106-109.

224. Runo J.R., Vnencak7Jones C.L., Prince M. et al. Pulmonary venoocclusive disease caused by an inherited mutation in bone morphogenetic protein receptor II. Am. J. Respir. Crit. Care Med. 2003; 167: 889-894.

225. Dufour B., Maitre S., Humbert M. et al. High-resolution CT of the chest in four patients with pulmonary capillary hemangiomatosis or pulmonary venoocclusive disease. Am. J. Roentgenol. 1998; 171: 1321-1324.

226. Resten A., Maitre S., Humbert M. et al. Pulmonary hypertension: CT of the chest in pulmonary venoocclusive disease. Am. J. Roentgenol. 2004; 183: 65-70.

227. Swensen S.J., Tashjian J.H., Myers J.L. et al. Pulmonary venoocclusive disease: CT findings in eight patients. Am. J. Roentgenol. 1996; 167: 937-940.

228. Rabiller A., Humbert M., Sitbon M. et al. Bronchoalveolar lavage as a diagnostic tool in pulmonary hypertension: occult alveolar hemorrhage is a common feature of pulmonary venoocclusive disease. Am. J. Respir. Crit. Care Med. 2004; 167: A276.

229. Palmer S.M., Robinson L.J., Wang A. et al. Massive pulmonary edema and death after prostacyclin infusion in a patient with pulmonary venoocclusive disease. Chest 1998; 113: 237-240.

230. Humbert M., Maitre S., Capron F. et al. Pulmonary edema complicating continuous intravenous prostacyclin in pulmonary capillary hemangiomatosis. Am. J. Respir. Crit. Care Med. 1998; 157: 1681-1685.